September 2, 2018

Disputations of the Benefits of Lipitor@Pfizer

MSP of British Columbia

These are the facts, in 2017:

  • 11.5% of Canada’s GDP was spent on Healthcare
    • totalling $242 billion
    • averaging $6,640 per Canadian
  • 28.3% was spent on Hospitals
    • averaging $1,871 per Canadian
  • 16.4% was spent on Drugs
    • averaging $1,086 per Canadian
  • 15.4% Physician costs round out the top three spending drivers, at 15.4 per cent per Canadian, or $1,014 per person.
  • Lipitor@Pfizer is the most successful and commonly prescribed medication in the world earning over $125 billion for the Pfizer corporation over the last 14 years
  • Lipitor@Pfizer (Atorvastatin) is a member of the drug class known as statins.
  • Lipitor@Pfizer inhibits (HMG-CoA) reducing the production of over 30,000 biomolecules such as cholesterol, vitamin K, coenzyme Q10, and all steroid hormones by up to 60%. This effect is biochemically unavoidable.
  • Due to toxicity the maximum allowable dose of Lipitor@Pfizer is 80 mg per day.

Pfizer’s net profit margin from 2006 to 2017 was 41.29%

  • Pfizer has a fiduciary duty to it’s stockholders.
  • Pfizer stocks are primarily held by institutional and mutual funds.
  • Pfizer has no legal duty to provide the best solution to its customers.
  • Pfizer controls regulatory bodies, influential practitioners, medical universities, ongoing physician training and customer information via stock participation, grants, funded research, mass marketing, direct marketing, kickbacks and benefits to physicians.
  • Corporate data used to secure regulatory approval is not available to the public.

This is refered to as regulatory capture.

The FDA conducted a 6-week inspection of Pfizer’s New York headquarters in July and August of 2009, where agency inspectors found system-wide lapses at the world’s largest drug manufacturer and in a 12-page warning letter to Pfizer Chief Executive Jeffrey Kindler, the FDA cited numerous examples of failing to report a growing number of serious side effects involving the company’s top selling cholesterol medication Lipitor@Pfizer dating back as far as 2004.

The most common adverse side effect of Lipitor@Pfizer is muscle pain referred to as Statin Induced Myphothy and Exercise Intolerance.

Myopathy is a disease of the muscle in which the muscle fibers do not function properly.

In 1989 Merck was issued patent (4,933,165) combining a statin and Coenzyme Q10 that was described as a pharmaceutical composition and method of counteracting HMG-CoA reductase inhibitor-associated myopathy.

Since 2000 Health Canada has issued five ADR advisories related to statins:

  • 2002 – Rhabdomyolysis and Myopathy
  • 2004 – Crestor and Rhabdomyolysis
  • 2005 – Existing conditions increase muscle problems
  • 2005 – Statins and memory loss
  • 2010 – Statins and interstitial lung disease

Between 2006 and 2013; 69,054 muscle-related, dose dependent adverse events from muscle pain to muscle cell damage and severe rhabdomyolysis were reported to Medwatch .

  • The 2005 Health Canada statement in the Canadian Adverse Reaction Newsletter suggested a possible association between statins and memory loss. The onset of these adverse events described in the case reports varied, but most occurred within 1 year of statin initiation. Most of the cases reported an improvement in cognitive symptoms once the statin was stopped or the dose reduced.
  • On February 28, 2012, the US FDA revised statin labels, warning of the potential for “generally non-serious and reversible cognitive side effects (memory loss, confusion, etc.) and reports of increased blood sugar and glycosylated hemoglobin (HbA1c) levels”.

Between 2006 and 2013 there were 38,508 cognitive and emotional adverse effects related to statins reported in the MedWatch database.

In 2017 an accredited BC psychiatrist refused to report an averse effect, because he could not “prove it”.

Medical Trial run-ins screen out patients who experience intolerance and adverse reactions to the medication.

Treating to New Targets Study (TNT)

Intensive lipid lowering with atorvastatin in patients with stable coronary disease funded by Pfizer, the TNT medical trial reported in 2005 studied 10,000 patients with stable Coronary Heart Disease (CHD) for 5 years. Patients were prescribed either 10 or 80 mg of Lipitor@Pfizer

  • 131 patients with myalgia (muscle pain) or abnormal liver tests were dropped during run in
  • A major cardiovascular event occurred in 548 (10.9 percent) of patients receiving 10 mg of atorvastatin
  • A major cardiovascular event occurred in 434 (8.7 percent) of patients receiving 80 mg of atorvastatin
  • 982 patients with stable CDC experienced a major cardiovascular event while taking Lipitor@Pfizer
  • There was no reduction in overall mortality between the two groups.
  • Patients prescribed 80 mg of Lipitor@Pfizer experienced a significant rate of adverse events compared to patients prescribed 10 mg.

There is NO reduction in mortality (Death) in CHD patients who are prescribed Lipitor@Pfizer.

Study of Coronary Atheroma by Travascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN (SATURN Trial)

Evaluated CRESTOR rosuvastatin 40 mg daily versus LIPITOR atorvastatin 80 mg daily in patients with coronary disease over 18 months.

  • 1578 Patients entered the Trial
  • 193 Patients dropped durning Run-In
  • 1385 Patients began the trial
  • 1039 Patients were treated for 104 weeks
  • 346 Patients left during the trial
  • 103 quit by preference of the patient
  • 101 had their first major cardiovascular event
  • 4 were dead
  • 34% of the patients that entered the trial did not finish
The JUPITER trial (Justification for the Use of Statins in Primary Prevention:

An Intervention Trial Evaluating Rosuvastatin trial) was a clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people with normal cholesterol levels. The JUPITER study studied people with cholesterol levels less than 130 mg/dL and no significant cardiovascular risk, but with elevated (hs-CRP) C-reactive protein (hs-CRP). The study demonstrated that cholesterol level appeared to have no relationship with cardiovascular disease risk…

People with low levels of cholesterol die from heart attacks all the time, even when they are taking the maximum allowable dose of 80 mg of Lipitor@Pfizer.

In 2005 Pfizer launched the The Maximum-Dose Lipitor® Campaign

The campaign began in earnest in 2005, after a study of maximum-dose Lipitor® for reducing heart attacks was published in the New England Journal of Medicine.  The study, known as the Treating New Targets (TNT) study, was funded by Pfizer, and it received glowing coverage from newspapers and news programs that described maximum-dose Lipitor® as if it was a medical breakthrough. Unfortunately, it was not. Yet the coverage made a strong impression, and so began the campaign to persuade doctors to medicate ever more patients with the most powerful, expensive dose of Lipitor® available.

As doctors prescribe more maximum-dose Lipitor® than ever, serious questions remain about maximum-dose Lipitor®. Is it effective? Is it worth the high cost? Is it safe? Statins are important drugs. Some people require strong statin treatment. Yet the great majority of people with elevated cholesterol do not need high doses of strong statins. The risk of side effects is greater with stronger doses than with milder ones. There is no scientific basis for using more medication than needed for any medical condition, and this applies particularly to the use of statin drugs. Treatment should be individualized. Safety should be emphasized. Over medication should be avoided. Side effects should be prevented. These are fundamental principles of medical science. The indiscriminate, widespread, “shotgun” use of maximum-dose Lipitor® violates all of them.

What happened to me was not a medical error

Icarus Flyby

My wife and I have contributed to healthcare budgets and costs since 1970 by payments to the Medical Services Plan of British Columbia via our employment, personal, business and property taxes. The year my wife retired, medical coverage under her pension plan was discontinued by the Province of British Columbia

In 2006 I had a heart attack and was prescribed 80 mg of Lipitor@Pfizer per day in order to lower my high cholesterol.

The lipid hypothesis is a medical theory postulating a link between blood cholesterol levels and the development, occurrence and prevention of heart disease and cardiovascular events.  Avoidable Medical Errors are the third leading cause of death and

Adverse Effects from medications are the leading medical error

Whatever the validity of lipid hypothesis, there are clear and substantial risks associated with taking Lipitor @ Pfizer which I took as prescribed for eight years, and I was not warned. 
As a result my life was transformed.  Icarus Flyby and the Rock from Mars is the story of this transformation.

theTotalPane @ 2018

It is no longer possible to trust much of the clinical research that is published or to rely on the judgement of trusted physicians or authoritative medical guidelines.

Dr. Marcia Angell, 20 year Editor of the New England Journal of Medicine


  • Post authorIcarus Flyby

    This is a very large problem with a very large problem and that is that there is a technical solution to the tools of misinformation and ignorance.

    Icarus Flyby

Comments & Reviews

This site uses Akismet to reduce spam. Learn how your comment data is processed.